Avtor/Urednik		Urdl, Wolfgang
Naslov		Hormone replacement therapy and breast cancer risk: current status after WHI study
Prevedeni naslov		Hormonsko nadomestno zdravljenje in tveganje raka na dojki: sedanje stanje po študiji WHI
Tip		članek
Vir		In: Takač I, Arko D, editors. 30 let Centra za bolezni dojk v Mariboru. Zbornik predavanj Simpozij z mednarodno udeležbo; 2003 maj 23; Maribor. Maribor: Splošna bolnišnica Maribor,
Leto izdaje		2003
Obseg		str. 29-35
Jezik		eng
Abstrakt		Between 1993 and 1998, more than 160,000 postmenopausal women, 50 to 79 years of age, were enrolled in a study by the Women's Health Initiative (WHI). This study was to be the first prospective randomized multi-center trial to evaluate the benefits and risks of estrogen replacement therapy (ERT) or hormone replacement therapy (HRT) in primarily healthy women without risk factors. The protocol of this study provided two groups of women in which hormone replacement therapy was given: Firstly, hysterectomied women were given ERT, secondly, women not hysterectomied were given a combined hormone substitution (HRT): 0.625 mg conjugated estrogen plus medroxyprogesterone acetate 2.5 mg per day. As primary endpoint of this study, the relative risk (RR) of cardiovascular diseases (myocardial infarction, death due to cardiovascular diseases) and the RR of invasive breast cancer, as secondary endpoint, the RR of pulmonary embolism, apoplectic insult, carcinoma of endometrium and colon, hip fracture and death due to other causes were evaluated. The end of this study was planned for March 2005, after 8.5 years. Surprisingly, at the end of May 2002, the study on women with HRT was stopped after 5.2 years, because the evaluation in-between showed a higher risk in comparison to the benefits. A higher risk of cardiovascular diseases, invasive breast carcinomas, pulmonary embolism, apoplectic insult could be found. In contrast, a significant decrease in the RR of colorectal cancer, endometrial cancer, hip fracture and death due to other causes could be shown. It was not amazing that this decision of the "Data and Safety Monitoring Board" released discussions all over the world. In this commentary, the current status regarding breast cancer risk in women with HRT after the WHI study is discussed.
Deskriptorji		ESTROGEN REPLACEMENT THERAPY BREAST NEOPLASMS